80results about How to "Effective immune protection" patented technology

The invention provides an I-group 4-type aviadenovirus genetic engineering subunit vaccine and a preparation method thereof. According to the technical scheme, the preparation method comprises the following steps: cloning an encoding gene of fibrous protein C-terminal from an I-group 4-type aviadenovirus genome according to a PCR technology and performing sequence analysis; cloning the gene to an expression vector pET-32a, transforming escherichia coli, constructing engineering bacteria, and inducing the engineering bacteria by isopropyl-beta-D-thiogalactopyranoside to express the fibrous protein C-terminal; performing lysis on an engineering bacterial cell, performing centrifugal separation on an inclusion body of the engineering bacterial cell, dissolving urea and diluting for renaturation; preparing the vaccine according to the conventional preparation method of a mineral oil adjuvant inactivated vaccine. According to the I-group 4-type aviadenovirus genetic engineering subunit vaccine prepared by the method, the immune effect of the vaccine is evaluated by a serological method and an immunity challenge method, and the result indicates that the aviadenovirus inactivated vaccine prepared by the method can provide effective immunoprotection and has a good commercialized development prospect.

The invention aims at providing a porcine pseudorabies virus vaccine. The porcine pseudorabies virus vaccine comprises an antigen and a protective agent, wherein the antigen contains an attenuated virus strain which is prepared after deleting virulence genes by a porcine pseudorabies virus strain with the collection number of CGMCC No. 10266. The prepared vaccine can effectively prevent porcine pseudorabies; furthermore, because the porcine pseudorabies virus as the antigen is a gene-deleted strain, by continuous passage of horizontally transmitted infections in mouse bodies, no virulence reversion occurs, and the genetic stability is realized, thereby being in line with the standard of having no virulence reversion in the porcine pseudorabies virus deleted vaccine strain; and the prepared vaccine can provide effective immune protection, and has great commercialization development prospects.

The invention aims at providing a porcine pseudorabies virus vaccine. The porcine pseudorabies virus vaccine consists of an antigen and a protective agent, wherein the antigen comprises an attenuated virus strain which is prepared by deleting virulence genes gE and gI of a porcine pseudorabies virus strain with a collection number of CGMCC No.10266. The prepared vaccine provided by the invention can be used for effectively preventing porcine pseudorabies; moreover, porcine pseudorabies virus which is taken as the antigen is a gene-deleted strain, and after the porcine pseudorabies virus is subjected to continuous passage in a mouse body by virtue of horizontal transmission infection, no virulence enhancement phenomenon can be caused, and thus the gene-deleted strain is stable in heredity, and can meet the standard that a porcine pseudorabies virus deleted vaccine strain does not have virulence enhancement; and the prepared vaccine can be used for providing effective immune protection, and has very good commercialized development prospects.

The invention aims at providing a porcine pseudorabies virus vaccine. The porcine pseudorabies virus vaccine comprises an antigen and a protective agent, wherein the antigen contains an attenuated virus strain which is prepared after deleting virulence genes, namely TK, gE and gI, by a porcine pseudorabies virus strain with the collection number of CGMCC No. 10266. The prepared vaccine can effectively prevent porcine pseudorabies; furthermore, because the porcine pseudorabies virus as the antigen is a gene-deleted strain, by continuous passage of horizontally transmitted infections in mouse bodies, no virulence reversion occurs, and the genetic stability is realized, thereby being in line with the standard of having no virulence reversion in the porcine pseudorabies virus deleted vaccine strain; and the prepared vaccine can provide effective immune protection, and has great commercialization development prospects.

The invention discloses a veterinary clostridium septicum toxin, a preparation method thereof and a special culture medium. Every 100 ml of culture medium is prepared from 1.5-2.0 g of proteose peptone, 1.5-2.0 g of casein peptone, 0.5-0.75 g of yeast extract powder, 0.14-0.28 mg of ZnSO4.7H2O, 0.5-0.75 g of Na2HPO4.12H2O, 0.03-0.045 g of KH2PO4, 1-1.5 g of glucose and the balance water; the pH value of the culture medium is 7.5-8.0. The veterinary clostridium septicum toxin is obtained by inoculating a production strain of clostridium septicum into the culture medium, collecting a culture object, conducting centrifugation and filtering a supernatant. By means of the method, the highest toxicity can be raised up to 10 times that of the vaccine-making standard of regulations for veterinarybiological products in China, and the output-input ratio can be increased to 20 times that of an original traditional process. Moreover, the neutralizing titers of toxoid vaccines prepared by using the veterinary clostridium septicum toxin to corresponding serums of rabbits and sheep are also increased to 8 times that of the regulation standard respectively.

The invention relates to identification of a Haemophilus parasuis (Hps) immunoprotecive antigen, separation and cloning of a protein gene and application of a protein coded by the Hps immunoprotecive antigen in a vaccine. According to the invention, a new protein CdtB having immunogenicity is separated from Hps (the culture collection number is CVCC3361), and the nucleotide sequence is shown as SEQ ID NO:2 in a sequence table and is formed by coding 277 amino acids. The CdtB is a new protein having immunogenicity and can provide effective immunoprotection for Hps infection in mice. The invention also comprises preparation of an Escherichia coli recombinant bacterium BL21/Hps-CdtB expressing the immunogenicity protein gene CdtB. The recombinant Hps CdtB protein expressed by the invention has favorable safety and protection efficacy, and the immunoprotection effect is up to 70%.

The invention relates to a DNA vaccine for preventing AIDS, the vaccine is the recombinant nucleotide of Gag, Pol and Env nucleotide sequence through the artificial modification of structural protein containing encoded Human Immunodificidncy Virus-1 (HIV-1), these vaccines are used as the transcript units for the biological synthesis of the virus protein antigen when applied in vivo. The beneficial effects of the invention include, (1) improved DNA vaccine manufacturing technique, (2) no integration indication detected, (3) the vaccine target antigen includes almost all the HIV-1 structural protein, such as GagPol and Env.

The invention relates to an Eimeria maxima DNA vaccine of chicken, belonging to the field of biological veterinary drugs. A gene fragment Em8 of an antigen EmTFP250 at the spore stage of the Eimeria maxima of the chicken is cloned by utilizing the molecular biology technology, and the fragment has higher antigen index and the centralized T cell epitope. The gene fragment is connected with a chicken interleukin-2 (chIL-2) gene in series, thereby constructing a vaccine expression vector pVAX-Em8-IL-2. The vaccine contains a plurality of T cell immune response elements and has the advantages of high safety, long maintenance time in vivo, simple preparation, good thermal stability, convenient storage and transport, time-saving and effort-saving use, and the like. Experiments prove that the immune regulatory DNA vaccine pVAX-Em8-IL-2 has good immune protection effect on the anti-Eimeria maxima infection.

The invention provides a replication defective recombinant adenovirus vector vaccine for preventing AIDS. The recombinant adenovirus vaccine contains a nucleotide sequence which can encode human immunoddficiency virus-1 (HIV-1) structural proteins. A transcription unit contained in the recombinant adenovirus vaccine encodes HIV-1B/C recombinant complete core protein Gag, enzyme proteins coding Pol and outer membrane protein Env. In addition, in order to improve the efficiency of gene expression, the recombinant adenovirus ultimately selects modified Gag and Pol genes and wild type Env gene.

The invention discloses a pseudorabies virus gene engineering gB recombinant attenuated vaccine strain and application thereof. CRISPR/Cas9 is combined with techniques such as homologous recombination, and a genome of a pseudorabies virus vaccine strain Bartha-K61 is taken as a framework, and a recombinant pseudorabies virus strain Bar-JS-gB (BJB) is successfully acquired by replacing a gB gene of the Bartha-K61 with a gB gene of an epidemic pseudorabies virus variant JS-2012 in China. The strain BJB has stable heredity, and an immune mouse processed by an inactivated vaccine prepared by taking the strain BJB as a vaccine strain has relatively good capacity of effectively resisting attacking of a virulent strain JS-2012 than an immune mouse processed by an inactivated vaccine prepared from the Bartha-K61. Therefore, the strain BJB has relatively good immunogenicity, can be used for effectively controlling the prevalence of a PRV variant in China and can play an important role on control of pseudorabies.

The invention relates to a helicobacter pylori dominant antigen assembly based on CD4+T cell immunity and a preparation method. The dominant antigen assembly comprises the following three components and homologous protein of the three components: inosine monophosphate dehydrogenase, type II citrate synthase and urease B subunit, wherein the amino acid sequences are shown as SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3. The screened dominant antigen assembly based on CD4+T cell immunity has the obvious immune protection effect, has the protection effect superior to that of H.pylori holoprotein antigen, has strong capacity of scavenging helicobacter pylori, and causes extremely slight pathological injuries. The three immunity dominant antigens provided by the invention can induce the body to generate strong immune response reaction aiming at antigens, therefore, through the means of inducing the body to generate the response aiming at the immunoprotecive dominant antigens, or directly immunizing the body by adopting the protective antigens, the effective immune protection effect can be achieved on the helicobacter pylori infection, and the scheme can be used for the further study on the preventive and therapeutic polyvaccines of helicobacter pylori.

The invention provides a duck adenovirus 2 and DPV (Muscovy duck parvovirus) disease combined inactivated vaccine. Antigens are inactivated duck adenovirus 2 and DPV, wherein the preservation number of the DPV is CCTCC NO:V201812, and the preservation number of the duck adenovirus 2 is CCTCC No:V201633. The prepared duck adenovirus 2 and DPV disease combined inactivated vaccine is good in safety and any local and general side effects caused by the vaccine are prevented. The analysis for character, safety test and efficacy test data in retention period tests indicates that all indexes are stable and effective; the immune effect of the vaccine is evaluated with a serological method and an immune challenge method, a result shows that the combined inactivated vaccine can provide effective immune protection for ducks and has good commercialized development prospect.

The invention provides a live avian encephalomylitis and henpox combined vaccine. The combined vaccine consists of an antigen and a protective agent, wherein the antigen comprises henpox virus and avian encephalomylitis virus with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.8505. The combined vaccine prepared by the invention can be used for preventing avian encephalomylitis and henpox at the same time to achieve the aim of preventing two viruses with one injection. Furthermore, The avian encephalomylitis virus screened by the invention is an attenuated virus, performs serial passage in an avian body through horizontal transmitted infection, does not have the phenomenon of virulence return, is stable in heredity, and accords with the standard of no virulence return of an avian encephalomylitis attenuated vaccine strain; the prepared vaccine can provide effective immune protection, and has good commercial development prospect.

The invention provides a method for manufacturing high-strength typhoon prevention cloth, which comprises the following steps of: sufficiently mixing 100 parts by weight of polymer resin, 5 to 8 parts by weight of bridging agent and 10 to 100 parts by weight of solvent; uniformly coating the mixture on the surface of a foundation; carrying out drying treatment on the foundation to form a semifinished product, so that the semifinished product has functions of fire resistance, solarization resistance, waterproofness, antibacterial and antifungal performance and the like; and carrying out hole rolling treatment on the semifinished product by selecting a pin wheel device with suitable pin diameter and pitch to form a plurality of breathable micropores on the semifinished product, so that the manufacturing of the typhoon prevention cloth with air permeability can be completed.

The invention relates to immunity-protective Acinetobacter baumannii surface antigen SurAl and belongs to bacterial surface antigen recombinant proteins. The amino acid sequence of the immunity-protective Acinetobacter baumannii surface antigen SurAl is shown in SEQ ID No. 1; the nucleotide of the immunity-protective Acinetobacter baumannii surface antigen SurAl is encoded, under a sequence shown in SEQ ID No.2. The immunity-protective Acinetobacter baumannii surface antigen SurAl has low toxicity to human pulmonary epithelial cells A549, provides effective immunity protection for mice from being infected by Acinetobacter baumannii, and can be used as a candidate antigen for the development of subunit vaccines of Acinetobacter baumannii.

The invention relates to the technical fields of cytobiology, genetic engineering and animal biological products, in particular to a construction method and application of a Marc-145 stable cell strain. The invention provides the construction method of the cell strain for porcine reproductive and respiratory syndrome virus (PRRSV) reproduction, the construction method comprises the following stepsthat 1), a CD163 gene and a SBQ gene are correspondingly constructed to an lentiviral vector, and a recombination lentiviral vector is obtained; 2), the recombination lentiviral vector and a virus rescue auxiliary plasmid are together transmitted into a mammalian cell, the cell is cultured to obtain recombination viruses; and 3) the recombination viruses in the steps 2) infect a Marc-145 cell, and the Marc-145 stable cell strain is obtained. The invention further provides use of the cell. An inheritable character of the cell is stable, and the cell is sensitive to PRRSV, and has very good application prospects.

The invention relates to identification of a Haemophilus parasuis immunoprotective antigen, separation and cloning of protein gene, and application of coding protein thereof in vaccines. According to the invention, a new immunogenic protein CdtC is separated from Haemophilus parasuis (Hps) (the culture collection number is CVCC3361), the nucleotide sequence is disclosed as SEQ ID NO:2 in the sequence table, and the protein CdtC codes 176 amino acids. The CdtC is a new immunogenic protein, and can provide effective immunoprotection for mice infected by Haemophilus parasuis. The invention also relates to preparation of Escherichia coli recombinant bacterium BL21/Hps-CdtC for expressing the immunogenic protein gene CdtC. The recombinant Haemophilus parasuis CdtC protein expressed in the invention has favorable safety and protection efficacy, and the immunoprotection effect reaches 60%.

The present invention refers to a pharmaceutical composition comprising an isolated antiangiogenic peptide or a recombinant protein comprising the antiangiogenic peptide, wherein the peptide is between 11 and 40 amino acids in length and having antiangiogenic activity, the peptide comprising the amino acid sequence: X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14, wherein X1 is any amino acid residue compatible with forming a helix; X2 is an amino acid residue of: Leu, Ile, Val; X3 is an amino acid residue of: Arg, Lys, His, Ser, Thr; X4 is an amino acid residue of: Ile, Leu, Val; X5 is any amino acid residue compatible with forming a helix; X6 is an amino acid residue of: Leu, Ile, Val; X7 is an amino acid residue of: Leu, Ile, Val, Ser, Thr; X8 is any amino acid residue compatible with forming a helix; X9 is any amino acid residue compatible with forming a helix; X10 is an amino acid residue of: Gln, Glu, Asp, Arg, His, Lys, Asn; X11 is an amino acid residue of: Ser, Thr; X12 is an amino acid residue of: Trp, Tyr, Phe; X13 is an amino acid residue of: Leu, Ile, Val, Asn, Gln; X14 is an amino acid residue of: Glu, Gln, Asp, Asn.

The invention relates to an attenuated strain of a duck reovirus and application of the attenuated strain. The attenuated strain Q of the duck reovirus is obtained by attenuating a virulent strain 17117 of the duck reovirus through continuous passage on a Vero cell; a proliferation level on the Vero cell is high; and after being vaccinated, one-day old ducklings have no obvious clinical symptoms and pathological changes, and thus, the attenuated strain is high in safety. By vaccinating the one-day old ducklings with live vaccines prepared from the attenuated strain Q, effective immune protection can be generated.

The invention discloses an immunogen and antibody composite vaccine and a preparation method thereof. The composite vaccine consists of an immunogen at the center, an oil phase for coating the immunogen at the middle, and an antibody for coating the oil phase at the outer part, therefore, a water-in-oil-in-water (W/O/W) type emulsion system is formed. Within several hours after the composite vaccine is injected, the antibody is firstly and quickly released in the early stage, and then is absorbed by an organ and enters blood for immunization; the immunogen is then released, and is induced to generate effective active immunity within 4 to 6 days before the antibody loses the immunity. The composite vaccine has the advantage that seamless connection between specific passive immunity and specific active immunity is realized, adding complementation is achieved, and an effect can be taken quickly.

The invention discloses a preparation method and a product of a chicken infectious bursal disease virus antigen. A chicken infectious bursal disease virus VP2/4/3 polyprotein gene and a VP2 gene are optimized. The optimized chicken infectious bursal disease virus VP2/4/3 polyprotein gene or the VP2 gene is expressed in a silkworm bioreactor. The invention further discloses a preparation method of a chicken infectious bursal disease nucleic acid vaccine. The preparation method comprises the following steps: cloning the optimized chicken infectious bursal disease virus VP2/4/3 polyprotein gene or the VP2 gene into a baculovirus transfer vector controlled by a mammal promoter to be recombined with baculovirus to infect an insect host, presenting an exogenous gene in the insect host to obtain the nucleic acid vaccine. The expressed antigen is used for preparing a vaccine for immunizing animals or the nucleic acid vaccine is used for immunizing animals through injection or oral taking, so that effective immune protection is provided for the animals.

The invention discloses a construction method of a multi-pathogen mycoplasma ovine pneumonia nucleic acid vaccine. The construction method comprises the following steps of: step 1, extracting a Mo/Mmc genome; step 2, obtaining a MoP113/MmcLppA gene; and step 3, constructing a pVAX1-P113-LppA co-expression vector and expressing in mammalian cells. According to the construction method disclosed by the invention, the pVAX1-P113-LppA co-expression vector is constructed through a gene engineering method on the basis of mycoplasma ovine pneumonia multi-epitope antigen genes MoP113 and MmcLppA which are screened out at an early stage; an indirect immunofluorescence technology is used for verifying an expression condition of recombinant plasmids in MDBK (MDBK); the nucleic acid vaccine is developed by selecting two different antigen genes and an immune protection effect can be effectively provided aiming at mycoplasma ovine pneumonia caused by Mo and Mmc infection; and a plurality of problems of current vaccine research and development are solved.